期刊
CANCER JOURNAL
卷 28, 期 5, 页码 369-376出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/PPO.0000000000000618
关键词
Head and neck squamous cell carcinoma; PI3K inhibitors; targeted therapy
类别
The PI3K pathway is abnormally activated in head and neck squamous cell carcinomas, making it a valuable target for targeted therapy. Multiple PI3K inhibitors have been studied but have shown unfavorable risk-benefit ratios in unselected patient populations. Buparlisib, a potent pan-class I PI3K inhibitor, has shown promising efficacy when combined with paclitaxel for advanced head and neck squamous cell carcinoma. Results of the phase III BURAN trial are pending.
The phosphoinositide 3-kinase (PI3K) pathway is aberrantly activated in most head and neck squamous cell carcinomas, making it a prized target for targeted therapy development. Multiple PI3K inhibitors have been studied in early phase trials, with unfavorable risk-benefit ratios in molecularly unselected patient populations. Buparlisib, a potent pan-class I PI3K inhibitor, shows promising efficacy in combination with paclitaxel for advanced head and neck squamous cell carcinoma. Results of the phase III BURAN trial are awaited.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据